Table 7.
Summary of recent clinical trials using MSCs for traumatic brain injury.
| Reference | Disease | Source | Number | Mean Age (Range), Year | Route of Administration | Number of Cells | Number of Treatments | Results | Adverse Events | |
|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | |||||||||
| Wang et al. [91] | Traumatic brain injury (Phase 2) |
UC | 20 | 20 | 27.5 ± 9.4 28.6 ± 10.1 |
IT | 6.0 × 107 cells | 4 | Comprehensive functional recovery and improvement in the ADL after 6 months |
Mild dizziness, headache |
| Tian et al. [92] | Traumatic brain injury | BM | 97 | 0 | - | IT | 3.0–5.0 × 106 cells | 1 | Improvement of consciousness and motor function after 14 days | No |
IT, intrathecal injection; BM, bone marrow; UC, Umbilical cord.